Erika Allred, MD, FABP, is a board-certified pediatrician working on multiple projects with Rady Children’s Institute for Genomic Medicine. In addition to her clinical duties, Dr. Allred is assisting partner sites – other children’s hospitals and health systems in the US and around the world – with their outreach and education regarding the clinical use and validity of rapid Whole Genome Sequencing™ in critically ill pediatric patients. Her recent research includes the evaluation of pediatric transplant patient outcomes along with the genomics of kidney disease, specifically the genetic overlap of congenital anomalies of the kidneys and urinary tract (CAKUT) system and congenital heart disease (CHD). Previously, Dr. Allred has worked on devising novel targeted therapies for muscular dystrophies, a group of neuromuscular diseases that cause weakness and degeneration of the skeletal muscles. Dr. Allred is currently completing her pediatric nephrology fellowship through UC San Diego School of Medicine and UC San Diego Health where she also did her residency. She received her Doctor of Medicine degree from the University of Nevada, Reno School of Medicine, after graduating Summa Cum Laude from the University of Nevada, Reno.
Clinical Dx showcase:
Rady Children’s Institute for Genomic Medicine®
Rady Children’s Institute for Genomic Medicine® is transforming neonatal and pediatric healthcare by offering the fastest delivery of rapid Whole Genome Sequencing™ to enable prompt diagnosis and targeted treatment of critically ill newborns and children in intensive care.
Changing Lives in Real Time with rWGS
Rady Children’s Institute for Genomic Medicine® performs the world’s fastest rapid Whole Genome Sequencing™, diagnosis, and reporting to drive Rapid Precision Medicine and unleash the power of rWGS to end the therapeutic odyssey for children suffering from rare genetic disease.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative